StockMarketWire.com - Cell-based medicines developer MaxCyte said it would hold a webinar for sell-side analysts on Tuesday to display its technology.

The presentation would demonstrate how its partners could create drugs using gene-editing technology in the treatment of inherited genetic diseases and cancer.




Story provided by StockMarketWire.com